Key facts
as of Sep 2026- Seaport Therapeutics’s last known valuation is $740.0M.
- It has raised $329.9M across 1 recorded rounds; the latest was Later Stage VC ($225.9M) in Oct 2024.
- Notable investors include General Atlantic, Goldman Sachs Asset Management, ARCH Venture Partners, Hawktail, T. Rowe Price Group — 13 tracked in total.
- 1 institutional filer reports fund marks on Seaport Therapeutics across 1 filings.
- Seaport Therapeutics has filed 1 Form D with the SEC, most recently Oct 2024 ($225.9M sold to 33 investors).
- Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence~$18per share
as of Sep 2026 · the exact daily mark is a member feature
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Seaport Therapeutics
Create free account
No card required
Recorded secondary trades
No prints on record
No secondary trades in Seaport Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
1 filers · latest May 20261 SEC-registered fund reported 1 fair-value mark on Seaport Therapeutics between May 2026 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
1 roundsAbout Seaport Therapeutics
Operator of a biopharmaceutical company intended to develop novel neuropsychiatric medicines in areas of patient need. The company's medicines offer oral bioavailability, bypassing first-pass metabolism and reducing hepatotoxicity and other side effects, enabling patients to live with neuropsychiatric disorders.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2020
- Employees
- 47
- Website
- seaporttx.com/
- Ownership
- Privately Held (backing)